Axon Enterprise, Inc (NASDAQ:AXON – Get Free Report) CEO Patrick Smith sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $500.00, for a total transaction of $5,000,000.00. Following the sale, the chief executive officer directly owned 3,050,997 shares in the company, valued at approximately $1,525,498,500. The trade was a 0.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Axon Enterprise Stock Performance
Shares of AXON stock opened at $560.61 on Wednesday. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average price of $426.15 and a 200-day moving average price of $481.27. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $885.91. The firm has a market capitalization of $45.19 billion, a PE ratio of 225.14, a P/E/G ratio of 10.42 and a beta of 1.45.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.90 million. During the same quarter in the prior year, the firm earned $1.47 earnings per share. The firm’s revenue for the quarter was up 33.7% compared to the same quarter last year. As a group, equities research analysts expect that Axon Enterprise, Inc will post 1.63 earnings per share for the current year.
Wall Street Analyst Weigh In
View Our Latest Research Report on AXON
Key Axon Enterprise News
Here are the key news stories impacting Axon Enterprise this week:
- Positive Sentiment: News that President Trump bought Axon shares and that ICE later sought a large Taser contract has fueled speculation about future government demand for Axon’s products. Trump bought as much as $5 million in Axon stock before ICE sought $220 million Taser deal
- Positive Sentiment: Axon’s recent operating momentum is also supporting the stock, including first-quarter revenue growth of 34% year over year and management’s raised 2026 growth outlook. Axon Enterprise jumps as investors react to disclosure-linked contract narrative and strong operating momentum
- Neutral Sentiment: Analysts remain generally constructive, with Northland Securities reiterating a buy rating and several recent price targets clustering well above prior trading levels. Northland Securities Reaffirms Their Buy Rating on Axon Enterprise (AXON)
- Neutral Sentiment: One headline also noted ongoing debate about valuation and whether the stock’s recent rebound is being driven more by momentum and political headlines than fundamentals. Axon Enterprise (AXON) Stock After Recent Volatility Is The Current Price Justified
- Negative Sentiment: The Trump-Axon-ICE connection has also raised ethics and conflict-of-interest questions, which could create political and reputational risk around government contracting. Axon Enterprise (AXON) Stock Drew Ethics Questions After Trump Bought $5 Million In Shares
- Negative Sentiment: Insider selling remains a headwind for sentiment, with the CEO recently selling shares under a pre-arranged trading plan and no insider purchases reported in the last six months. Axon Enterprise Stock Performance
Institutional Investors Weigh In On Axon Enterprise
Several hedge funds and other institutional investors have recently modified their holdings of AXON. Evergreen Capital Management LLC grew its holdings in Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the period. Quadrant Capital Group LLC raised its stake in shares of Axon Enterprise by 0.5% in the third quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company’s stock worth $2,848,000 after buying an additional 19 shares during the period. CWA Asset Management Group LLC lifted its position in shares of Axon Enterprise by 5.2% during the 4th quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company’s stock valued at $220,000 after buying an additional 19 shares in the last quarter. Synergy Financial Group LTD lifted its position in shares of Axon Enterprise by 1.4% during the 3rd quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock valued at $996,000 after buying an additional 19 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Axon Enterprise by 1.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock valued at $1,350,000 after acquiring an additional 19 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.
About Axon Enterprise
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
See Also
- Five stocks we like better than Axon Enterprise
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
